OTCQB:AGEEF - OTCQB:HMDEF - OTCQX:FCUUF - OTCQX:MMNFF - OTCQX:OGRMF - 24/7 Market News

Venture Breakfast Bits, by 24/7 Market News

2019-04-15T09:17:22+00:00 Apr. 15, 2019 9:15AM EDT|

DENVER, Colo., April 15, 2019- (24/7MarketNews via COMTEX) Venture Market News for April 15, 2019.

  • MedMen Releases Preliminary Third Quarter 2019 Systemwide Revenue Results - Designated News Release

MedMen Enterprises Inc. (“MedMen” or the “Company”) (CSE: MMEN) (OTCQX: MMNFF) (FSE: A2JM6N) announced today unaudited systemwide revenue for its fiscal 2019 third quarter ended March 30, 2019. Across the Company’s operations in California, Nevada, New York, Arizona and Illinois, systemwide revenue was US$36.6 million (CA$48.8 million). This represents a 22% quarter-over-quarter increase over its fiscal 2019 second quarter ended December 29, 2018. Systemwide revenue, pro forma for pending acquisitions that have not yet closed, was US$54.9 million (CA$73.2 million) for the quarter. For the third quarter, gross margin across its retail operations was 51%1, compared to 53% in the previous quarter. The Company is expected to post its fiscal 2019 third quarter results in May 2019.

Full press release

  • Organigram Reports Second Quarter Fiscal 2019 Results; Record Net Revenue of $26.9 Million

- Record net revenue of $26.9 million or more than double the net revenue of Q1-2019

- Adjusted gross margin of $16.0 million or 60%1

- Adjusted EBITDA of $13.3 million or adjusted EBITDA margin of 49%1

- As planned, an amendment to our licence for Phase 4a and 4b of the Moncton facility was submitted to Health Canada in March for the security perimeter as well as the initial 13 grow rooms in Phase 4a

- The Phase 4 expansion is being completed in a series of stages which once fully licensed will bring our annualized production up to 113,000 kg by the end of 2019

- Phase 5 refurbishment underway for an edibles and derivative facility and additional in-house extraction capacity

- Signed a letter of intent with the Société québécoise du cannabis (SQDC); one of only three licensed producers in Canada to be in all ten provinces

- Subsequent to quarter-end, all remaining convertible debentures converted which has removed approximately $49.3 million in current liabilities from the balance sheet 

MONCTON, NB, April 15, 2019 /CNW/ - Organigram Holdings Inc. (TSX VENTURE: OGI) (OTCQX: OGRMF), the parent company of Organigram Inc. (the "Company" or "Organigram"), a leading licensed producer of cannabis, is pleased to announce its results for the second quarter ended February 28, 2019 ("Q2" or "Q2 2019").  The Q2 2019 includes the first full quarter of adult-use recreational sales for the Company.

Full press release

  • Fission's PFS shows Low OPEX of US$6.77/lbs U3O8, High IRR and Clear Growth

- Results highlight increased indicated resources, the robust economics and long-term potential for the Triple R deposit

OTCQX SYMBOL: FCUUF

KELOWNA, BC, April 15, 2019 /CNW/ - FISSION URANIUM CORP. ("Fission" or "the Company") is pleased to announce the results of a Prefeasibility Study (the "PFS"), conducted by Roscoe Postle Associates Inc. ("RPA") and first-time estimate of Mineral Reserves for its' Patterson Lake South ("PLS") property in Canada's Athabasca Basin region. With an estimated OPEX of just US$6.77/lb U3O8 and an IRR (pre-tax) of 29%, the PFS further enhances the potential for highly-economic production at PLS. In addition, with the R780E zone still open at depth and along plunge to the east and the recently discovered high-grade mineralized zones along strike to the west and east (R1515W, R840W and R1620E zones) yet to be included in the reserve mine plan, there is clear upside for expanding the resource base and mine life and further improving the economics. The PFS is based on an open pit / underground hybrid operation and the Company is also progressing a PEA-level underground-only alternate scenario that indicates potential for improved economics.

Full press release

  • DionyMed Brands Inc. Announces C$10 Million Bought Deal Private Placement of Units Co-Led by Canaccord Genuity Corp. and Cormark Securities Inc. and Grants Option to Increase Deal Size to C$20 Million

TORONTO, April 15, 2019 /CNW/ - DionyMed Brands Inc. ("DionyMed" or the "Company") (CSE: DYME; OTCQB: HMDEF), a multi-state cannabis brands, distribution and direct-to-consumer delivery platform, is pleased to announce that it has entered into an agreement with a syndicate of agents co-led by Canaccord Genuity Corp. and Cormark Securities Inc. (collectively, the "Underwriters"), pursuant to which the Underwriters have agreed to purchase, on a bought deal private placement basis, 3,636,364 units of the Company (the "Units") at a price of C$2.75 per Unit (the "Issue Price") for aggregate gross proceeds to DionyMed of C$10,000,001 (the "Offering").

Full press release

  • Halo to Enter Hemp CBD Extraction Market

Halo Labs Inc. ("Halo" or the "Company") (NEO:HALO, OTC:AGEEF, Germany:A9KN) is pleased to announce that it has entered into a binding Letter of Intent to secure a purpose built hemp processing facility in Southern Oregon (the “Transaction”) to expand the Company’s production capabilities into manufacturing CBD isolate and distillate. Production at the facility is expected to start in the 3rd quarter of 2019.

Full press release

Connect with 24/7 Market News on social media

https://twitter.com/247MarketNewsHQ

https://www.facebook.com/247MarketNewsHQ/

About 24/7 Market News

As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information.  24/7 MN provides comprehensive corporate communications resources and tools to engage the investment community.

DISCLAIMER:

24/7 Market News (24/7MN) is a third party publisher and news dissemination service provider that produces regular sponsored and non-sponsored reports, articles, stock market blogs, and newsletters covering equities listed on the NYSE, NASDAQ and micro-cap exchanges. 24/7MN holds no investment licenses and is NOT a financial advisory firm, investment adviser, analyst, or broker-dealer and does not undertake any activities that would require such registration. 24/7MN's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities.

The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and based on publicly available information which is believed to be reliable. 24/7MN makes no representations as to the completeness, accuracy, or timeliness of the material provided and all materials are subject to change without notice. 24/7MN and/or its affiliates are not responsible for any gains or losses that result from the opinions expressed and are not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks.

For further information on 24/7 Market News, please go to www.247marketnews.com 

Forward-Looking Statements

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may," "future," "plan," or "planned," "will," or "should," "expected," "anticipates," "draft," "eventually," or "projected." You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and 24/7MN undertakes no obligation to update such statements

CONTACT:

24/7 Market News

Editor@247marketnews.com

Send this to a friend

Hi, this may be interesting you: Kraig Biocraft Laboratories’ New R&D Facility Extends Its Competitive Advantages and Prepares for Large Scale Production! This is the link: https://www.247marketnews.com/kraig-biocraft-laboratories-new-rd-facility-extends-its-competitive-advantages-and-prepares-for-large-scale-production/